Mental Health Awareness: To Take Antidepressants or Not: Separating Truth From Fallacy

May is Mental Health Awareness Month, a time to bring clarity, compassion, and evidence back into conversations that have long been clouded by stigma and misinformation. Few topics illustrate this better than antidepressants.

For many people, deciding whether to start medication is not simple. They’ve heard conflicting stories from friends, social media, or even past experiences. They may worry about “being on something forever,” or feel that taking medication means they “should be able to handle things on their own.” Add in the complexities of insurance coverage, prior authorizations, and pharmacy barriers, and it’s no surprise that many people hesitate — or stop treatment prematurely.

Let’s separate truth from fallacy.

Antidepressants Are Not a Last Resort — They Are Evidence‑Based Medicine

Antidepressants have been studied for decades. They are among the most researched medications in modern medicine, with strong evidence supporting their efficacy, safety, and tolerability across a wide range of depression‑related disorders, including:

• Major depressive disorder

• Generalized anxiety disorder

• Panic disorder

• PTSD (Post-Traumatic Stress Disorder)

• OCD (Obcessive Compulsive Disorder)

• Premenstrual dysphoric disorder

They are not “happy pills”, and they don’t change your personality. They help regulate the brain pathways involved in mood, sleep, energy, and emotional processing — the same way medications help regulate blood pressure or thyroid function.

Fallacy: “If I start medication, I’ll be on it forever.”

Truth: Most people take antidepressants for a defined period — often 6–12 months — while building stability, skills, and support. Some people benefit from longer treatment, especially if they’ve had multiple episodes. But the decision is individualized and collaborative.

Fallacy: “Antidepressants don’t work.”

Truth: For many people, they work very well. For others, the first medication may not be the right fit — and that’s normal. Primary care physicians and mental health clinicians have multiple medication classes to choose from, each with different mechanisms and side‑effect profiles. Finding the right option is a process, not a failure.

Fallacy: “Medication is the only treatment.”

Truth: Medication is one tool. Counseling, lifestyle interventions, sleep support, trauma‑informed care, and social connection all matter. Many people benefit most from a combination of medication and therapy.

Social workers, psychologists, and licensed counselors (including LCSWs and LCPCs) play a critical role in goal‑oriented, evidence‑based counseling. Affordable options exist, including community mental health centers, sliding‑scale clinics, and telehealth.

Fallacy: “If I’m struggling, I should wait until I’m worse.”

Truth: Early treatment leads to better outcomes. Untreated depression can worsen over time, affecting relationships, work, physical health, and safety. Seeking help early is an act of strength.

Insurance Barriers Are Real — and They Affect Care

Even when someone is ready for treatment, insurance hurdles can delay or derail care. Prior authorizations, medication tiering, and inconsistent coverage can make people feel defeated before they begin. These barriers are systemic — not personal failures.

Primary care teams help patients navigate these obstacles every day. Many banks and community organizations also offer free or low‑cost notary and document services, which can help patients complete insurance paperwork or financial assistance forms without added stress.

You Don’t Have to Decide Alone

If you’re unsure about antidepressants, talk with your primary care physician. We can help you understand your symptoms, your options, and what treatment could look like — without pressure. The goal is not to “convince” you of anything. The goal is to support your health, safety, and long‑term wellbeing.

There are many paths toward feeling better. Medication is one of them — and for many people, it’s a safe, effective, and life‑changing tool.

References:

1. Johnson CF, Maxwell M, Williams B, Dougall N, MacGillivray S. Dose‑response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta‑narrative synthesis. BMJ Med. 2022;1(1):e000109.

2. Bağcaz A, Özel B. The short‑term effectiveness of antidepressants in a transdiagnostic sample and determinants of side effects and medication nonadherence: an observational study. Front Psychiatry. 2026;16:1752173.

3. Crowe M, Inder M, McCall C. Experience of antidepressant use and discontinuation: a qualitative synthesis of the evidence. J Psychiatr Ment Health Nurs. 2022;30(1):21‑34.

4. Sirey JA, Banerjee S, Marino P, et al. Adherence to depression treatment in primary care: a randomized clinical trial. JAMA Psychiatry. 2017;74(11):1129‑1135.

5. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta‑analysis. Lancet. 2018;391(10128):1357‑1366.

6. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361(9358):653‑661.

7. Khan A, Faucett J, Lichtenberg P, Kirsch I, Brown WA. A systematic review of comparative efficacy of treatments and placebo for depression. PLoS One. 2012;7(7):e41778.

8. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry. 2009;66(8):848‑856.

9. Riddle M, Potter WZ. Antidepressant medication: mechanisms of action. Handb Exp Pharmacol. 2019;250:187‑207.

10. Corrigan PW, Watson AC. Understanding the impact of stigma on people with mental illness. World Psychiatry. 2002;1(1):16‑20.